National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- (-) Arthritis (130)
- Asthma (1)
- Back Health and Pain (2)
- Behavioral Health (1)
- Cancer (4)
- Cancer: Breast Cancer (1)
- Cancer: Cervical Cancer (1)
- Cardiovascular Conditions (4)
- Caregiving (1)
- Care Management (1)
- Children/Adolescents (6)
- Chronic Conditions (16)
- Clinical Decision Support (CDS) (1)
- Clinician-Patient Communication (3)
- Communication (3)
- Comparative Effectiveness (25)
- Complementary and Alternative Medicine (1)
- Cultural Competence (1)
- Decision Making (9)
- Depression (2)
- Diabetes (1)
- Digestive Disease and Health (1)
- Disparities (2)
- Education (1)
- Education: Patient and Caregiver (3)
- Elderly (4)
- Electronic Health Records (EHRs) (6)
- Evidence-Based Practice (7)
- Eye Disease and Health (1)
- Genetics (1)
- Guidelines (2)
- Healthcare-Associated Infections (HAIs) (3)
- Healthcare Cost and Utilization Project (HCUP) (4)
- Healthcare Costs (7)
- Healthcare Delivery (1)
- Healthcare Utilization (4)
- Health Information Technology (HIT) (12)
- Health Insurance (1)
- Health Literacy (6)
- Health Promotion (2)
- Health Status (4)
- Heart Disease and Health (3)
- Hepatitis (1)
- Hospitalization (1)
- Hospital Readmissions (2)
- Imaging (1)
- Infectious Diseases (1)
- Injuries and Wounds (4)
- Kidney Disease and Health (1)
- Learning Health Systems (1)
- Lifestyle Changes (3)
- Low-Income (2)
- Medicare (3)
- Medication (28)
- Men's Health (1)
- Mortality (2)
- Obesity (3)
- Obesity: Weight Management (2)
- Opioids (1)
- Orthopedics (15)
- Osteoporosis (3)
- Outcomes (18)
- Pain (17)
- Patient-Centered Outcomes Research (38)
- Patient Adherence/Compliance (4)
- Patient and Family Engagement (4)
- Patient Experience (1)
- Patient Safety (6)
- Patient Self-Management (2)
- Practice Patterns (1)
- Pregnancy (2)
- Prevention (2)
- Provider: Physician (1)
- Quality Improvement (4)
- Quality Indicators (QIs) (1)
- Quality Measures (3)
- Quality of Care (7)
- Quality of Life (5)
- Racial and Ethnic Minorities (8)
- Registries (14)
- Research Methodologies (2)
- Respiratory Conditions (1)
- Risk (16)
- Sex Factors (2)
- Sexual Health (3)
- Skin Conditions (2)
- Sleep Problems (1)
- Social Determinants of Health (4)
- Stroke (2)
- Surgery (23)
- Telehealth (2)
- Tobacco Use (2)
- Treatments (5)
- Vaccination (2)
- Women (4)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
101 to 125 of 130 Research Studies DisplayedSingh JA, Cameron C, Noorbaloochi S
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
The researchers sought to determine whether biological drugs are associated with an increased risk of serious infection compared with traditional disease-modifying antirheumatic drugs (DMARDs). They found that standard-dose and high-dose biological drugs, with or without traditional DMARDs, are associated with an increase in serious infections in rheumatoid arthritis compared with traditional DMARDs, although low-dose biological drugs are not.
AHRQ-funded; HS021110.
Citation: Singh JA, Cameron C, Noorbaloochi S .
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet 2015 Jul 18;386(9990):258-65. doi: 10.1016/s0140-6736(14)61704-9.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research
Ranganath VK, Motamedi K, Haavardsholm EA
Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.
This study evaluated the effect of sustained American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission on residual joint inflammation assessed by magnetic resonance imaging (MRI) and to secondarily
evaluate other clinical definitions of remission, within an early seropositive rheumatoid arthritis (RA) cohort. It found that total MRI inflammatory scores (tenosynovitis, synovitis, osteitis) were lower among patients in clinical remission. Lower MRI scores were correlated with longer duration of Clinical Disease Activity Index (CDAI) remission.
evaluate other clinical definitions of remission, within an early seropositive rheumatoid arthritis (RA) cohort. It found that total MRI inflammatory scores (tenosynovitis, synovitis, osteitis) were lower among patients in clinical remission. Lower MRI scores were correlated with longer duration of Clinical Disease Activity Index (CDAI) remission.
AHRQ-funded; HS018517.
Citation: Ranganath VK, Motamedi K, Haavardsholm EA .
Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.
Arthritis Care Res 2015 Jul;67(7):929-39. doi: 10.1002/acr.22541..
Keywords: Arthritis, Imaging, Comparative Effectiveness
LoVerde ZJ, Mandl LA, Johnson BK
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. It found that in a high-volume center, with high RA-specific experience, RA does not increase postoperative AE.
AHRQ-funded; HS016075.
Citation: LoVerde ZJ, Mandl LA, Johnson BK .
Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study.
J Rheumatol 2015 Jul;42(7):1123-30. doi: 10.3899/jrheum.141251..
Keywords: Adverse Events, Arthritis, Surgery, Comparative Effectiveness, Patient-Centered Outcomes Research
Kim SC, Glynn RJ, Giovannucci E
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.
This study assessed the risk of high-grade cervical dysplasia, a surrogate endpoint for cervical cancer and cervical cancer, in women with systemic inflammatory diseases (SID), including IBD, psoriasis, rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), compared with the risk in women without SID. It found that the risk of high-grade cervical dysplasia and cervical cancer was 1.5 times higher in women with RA and SLE than in those without SID.
AHRQ-funded; HS018533.
Citation: Kim SC, Glynn RJ, Giovannucci E .
Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.
Ann Rheum Dis 2015 Jul;74(7):1360-7. doi: 10.1136/annrheumdis-2013-204993..
Keywords: Arthritis, Risk, Women, Cancer: Cervical Cancer, Cancer
Yazdany J, Dudley RA, Chen R
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
The aim of this study was to conduct the first systematic, national investigation of how Part D plans cover biologic disease-modifying anti-rheumatic drugs (DMARDs) and to determine patients’ financial burden under current cost-sharing structures. It found that all Medicare Part D drug plans cover at least 1 biologic DMARD, access is highly controlled through prior authorization requirements, and beneficiaries face significant cost sharing.
AHRQ-funded; HS017723; HS016772.
Citation: Yazdany J, Dudley RA, Chen R .
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Arthritis Rheumatol 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079..
Keywords: Medicare, Medication, Healthcare Costs, Arthritis
Kavanaugh A, Lee SJ, Curtis JR
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis achieving good clinical responses, provided patients maintain clinical benefit. Using data from the Corrona registry, the investigators found that discontinuation of a first course of tumour necrosis factor inhibitor may be associated with persistent clinical benefit. Half of the registry patients included in the study maintained response through 20 months.
AHRQ-funded; HS018517.
Citation: Kavanaugh A, Lee SJ, Curtis JR .
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Ann Rheum Dis 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435.
.
.
Keywords: Medication, Patient-Centered Outcomes Research, Registries, Arthritis
Solomon DH, Reed GW, Kremer JM
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
The researchers studied whether time-averaged disease activity in rheumatoid arthritis (RA) correlates with cardiovascular (CV) events. They found that reduced time-averaged disease activity in RA is associated with fewer CV events.
AHRQ-funded; HS018517.
Citation: Solomon DH, Reed GW, Kremer JM .
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Arthritis Rheumatol 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.
.
.
Keywords: Cardiovascular Conditions, Heart Disease and Health, Arthritis, Risk, Stroke
Yun H, Xie F, Delzell E
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
The researchers compare the subsequent risk of hospitalized infections associated with specific biologic agents among RA patients previously hospitalized for infection while receiving anti-tumor necrosis factor (anti-TNF) therapy. They found that among rheumatoid arthritis patients who experienced a hospitalized infection while on anti-TNF therapy, abatacept and etanercept were associated with the lowest risk of a subsequent infection compared to other biologic therapies.
AHRQ-funded; HS021694; HS023009; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Ann Rheum Dis 2015 Jun;74(6):1065-71. doi: 10.1136/annrheumdis-2013-204011..
Keywords: Arthritis, Healthcare-Associated Infections (HAIs), Healthcare-Associated Infections (HAIs), Patient-Centered Outcomes Research, Patient Safety
Curtis JR, Xie F, Yun H
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
The researchers evaluated rates of hospitalized infection among patients treated with biologic agents for RA who subsequently initiated denosumab in order to assess whether rates of infection were increased with concurrent biologic agent use for RA. They found that the rate of hospitalized infection among RA patients receiving denosumab concurrently with biologic agents for RA was not increased compared to those receiving zoledronate.
AHRQ-funded; HS018517
Citation: Curtis JR, Xie F, Yun H .
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Arthritis Rheumatol. 2015 Jun;67(6):1456-64. doi: 10.1002/art.39075..
Keywords: Arthritis, Healthcare-Associated Infections (HAIs), Risk, Patient Safety, Comparative Effectiveness
Burton MJ, Curtis JR, Yang S
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
The researchers evaluated the safety of current treatment regimens for patients with rheumatoid arthritis (RA) and HBV in a large US cohort. They found a low rate of hepatotoxicity among a large cohort of US veterans with RA and HBV infection who were prescribed conventional RA therapies. Also, there were comparable rates of hepatotoxicity between biologic and nonbiologic disease-modifying anti-rheumatic drugs.
AHRQ-funded; HS023710.
Citation: Burton MJ, Curtis JR, Yang S .
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Arthritis Res Ther 2015 May 22;17:136. doi: 10.1186/s13075-015-0628-z..
Keywords: Arthritis, Patient Safety, Medication, Hepatitis, Adverse Drug Events (ADE)
Petrov ME, Goodin BR, Cruz-Almeida Y
Disrupted sleep is associated with altered pain processing by sex and ethnicity in knee osteoarthritis.
This study examines the association between sleep disruption with increased pain sensitivity and enhanced pain facilitation in addition to reduced pain inhibition in persons with chronic pain such as knee OA. It found that disrupted sleep was associated with altered pain processing by sex and ethnicity/race.
AHRQ-funded; HS013852.
Citation: Petrov ME, Goodin BR, Cruz-Almeida Y .
Disrupted sleep is associated with altered pain processing by sex and ethnicity in knee osteoarthritis.
J Pain 2015 May;16(5):478-90. doi: 10.1016/j.jpain.2015.02.004..
Keywords: Pain, Sleep Problems, Arthritis, Racial and Ethnic Minorities, Sex Factors
Zhang J, Xie F, Delzell E
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
The purpose of this study was to examine whether concomitant methotrexate (MTX) use is associated with better biologic persistence and whether self-administered anti–tumor necrosis factor (anti-TNF) therapies are used at reduced doses in real world clinical care settings, not just clinical trials. It found that use of concomitant MTX is associated with greater persistence to biologic therapy.
AHRQ-funded; HS018517.
Citation: Zhang J, Xie F, Delzell E .
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care Res 2015 May;67(5):624-32. doi: 10.1002/acr.22510..
Keywords: Arthritis, Comparative Effectiveness, Patient-Centered Outcomes Research, Treatments
Singh JA, Inacio MC, Namba RS
Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.
This study examined whether an underlying diagnosis of rheumatoid arthritis (RA) or osteoarthritis (OA) impacts the 90-day readmission rates after total hip arthroplasty (THA) or total knee arthroplasty (TKA). The 90-day post arthroplasty readmission risk after THA or TKA is higher in patients with rheumatoid arthritis (RA) compared to osteoarthritis.
AHRQ-funded; HS021110.
Citation: Singh JA, Inacio MC, Namba RS .
Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.
Arthritis Care Res 2015 May;67(5):718-24. doi: 10.1002/acr.22497..
Keywords: Arthritis, Hospital Readmissions, Arthritis, Surgery
Yun H, Xie F, Delzell E
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
This study evaluated whether the risks of herpes zoster (HZ) differed by biologic agents with different mechanisms of action (MOAs) in older rheumatoid arthritis (RA) patients. Using Medicare data from 2006–2011, the researchers found that among RA patients, the rate and adjusted hazard ratios of HZ were similar among biologic agents, including those with non–tumor necrosis factor mechanisms of action.
AHRQ-funded; HS021694; HS018517.
Citation: Yun H, Xie F, Delzell E .
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care Res 2015 May;67(5):731-6. doi: 10.1002/acr.22470..
Keywords: Arthritis, Risk, Patient Safety, Patient-Centered Outcomes Research
Newman ED, Lerch V, Billet J
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
To improve the quality of care for patients with rheumatic disease, the researchers developed electronic data capture, aggregation, display, and documentation software. They found that their software was adopted for use by 86% of patients and rheumatologists. They concluded that the software was well-adopted by patients and providers. Post-implementation, significant improvements in quality of care, efficiency of care, and productivity were demonstrated.
AHRQ-funded; 290200600019I.
Citation: Newman ED, Lerch V, Billet J .
Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software.
Arthritis Care Res 2015 Apr;67(4):546-53. doi: 10.1002/acr.22479..
Keywords: Health Information Technology (HIT), Quality of Care, Arthritis, Patient-Centered Outcomes Research
Harrold LR, Reed GW, Kremer JM
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
The investigators compared the effectiveness of abatacept (ABA) versus a subsequent anti-tumour necrosis factor inhibitor (anti-TNF) in rheumatoid arthritis (RA) patients with prior anti-TNF use. They found that RA patients with prior anti-TNF exposures had similar outcomes if they switched to a new anti-TNF as compared with initiation of ABA.
AHRQ-funded; HS018517.
Citation: Harrold LR, Reed GW, Kremer JM .
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
Ann Rheum Dis 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936.
.
.
Keywords: Comparative Effectiveness, Medication, Patient-Centered Outcomes Research, Arthritis
Bannuru RR, Schmid CH, Kent DM
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
To determine the relative efficacy of the primary knee osteoarthritis (OA) treatments, the researchers performed a comprehensive review of the literature, using a network meta-analysis design. Their comparison of seven different medications found that intra-articular (IA) treatments (IA corticosteroids, IA hyaluronic acid) were superior to non-steroidal anti-inflammatory drugs.
AHRQ-funded; HS021396; HS018574
Citation: Bannuru RR, Schmid CH, Kent DM .
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Ann Intern Med. 2015 Jan 6;162(1):46-54. doi: 10.7326/M14-1231..
Keywords: Comparative Effectiveness, Medication, Arthritis, Outcomes, Pain
Singh JA, Lewallen DG
Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends.
The researchers examined the time-trends in key demographic and clinical characteristics of patients undergoing primary total hip arthroplasty (THA). They found that obesity, medical and psychological comorbidity increased and the underlying diagnosis of RA/inflammatory arthritis decreased rapidly in primary THA patients over 13-years.
AHRQ-funded; HS021110.
Citation: Singh JA, Lewallen DG .
Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends.
BMC Musculoskelet Disord 2014 Dec 17;15:441. doi: 10.1186/1471-2474-15-441..
Keywords: Surgery, Obesity, Risk, Registries, Arthritis
Curtis JR, Chen L, Bharat A
Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
In order to address a gap in linkage methodology, the researchers sought to link a large, de-identified outpatient registry of patients with rheumatoid arthritis with national Medicare administrative claims data. The purpose of their report was to describe the methods and validity of this linkage.
AHRQ-funded; HS018517
Citation: Curtis JR, Chen L, Bharat A .
Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
Arthritis Care Res. 2014 Dec;66(12):1790-8. doi: 10.1002/acr.22377..
Keywords: Arthritis, Registries, Comparative Effectiveness
Ghomrawi HM, Alexiades M, Pavlov H
Evaluation of two appropriateness criteria for total knee replacement.
The researchers evaluated the performance of 2 sets of non-U.S. appropriateness criteria (one from Spain and the other from Canada) for total knee replacement (TKR) in a group of 508 TKR patients. Although only 4.7 percent were classified as inappropriate by both sets of criteria, there was little agreement between the two.
AHRQ-funded; HS016075
Citation: Ghomrawi HM, Alexiades M, Pavlov H .
Evaluation of two appropriateness criteria for total knee replacement.
Arthritis Care Res. 2014 Nov;66(11):1749-53. doi: 10.1002/acr.22390..
Keywords: Surgery, Arthritis, Decision Making
Baddley JW, Winthrop KL, Chen L
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
The purpose of this paper was to determine, among patients with autoimmune diseases in the USA, whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor alpha inhibitors (TNFI), when compared to users of non-biological agents used for active disease. The investigators concluded that in the USA, the rate of non-viral OI was higher among new users of TNFI with autoimmune diseases compared to non-biological disease-modifying antirheumatic drugs users.
AHRQ-funded; HS017552; HS018517; HS017919.
Citation: Baddley JW, Winthrop KL, Chen L .
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
Ann Rheum Dis 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407..
Keywords: Arthritis, Comparative Effectiveness, Medication, Patient Safety
Curtis JR, Zhang J, Xie F
Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
The researchers aimed to examine the epidemiology of methotrexate (MTX) use among rheumatoid arthritis patients initiating MTX, including dosing, method of administration (oral versus subcutaneous (SC)) , and persistence. They also compare the effectiveness of 2 strategies in regard to delaying or avoiding use of biologic agents: switching to SC MTX or adding another nonbiologic disease-modifying antirheumatic drug.
AHRQ-funded; HS018517
Citation: Curtis JR, Zhang J, Xie F .
Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
Arthritis Care Res. 2014 Nov;66(11):1604-11. doi: 10.1002/acr.22383..
Keywords: Arthritis, Comparative Effectiveness, Medication
Goode AP, Shi XA, Gracely RH
Associations between pressure-pain threshold, symptoms, and radiographic knee and hip osteoarthritis.
The researchers sought to determine the association between generalized evoked pressure pain sensitivity with distal pressure–pain threshold and the presence, severity, or number of involved knee/hip joints with radiographic osteoarthritis or related symptoms. They found that as a participant’s sensitivity for pressure pain decreased, there were several significant associations with presence, severity, and number of joints with symptoms, regardless of the knee or hip joint.
AHRQ-funded; HS019479
Citation: Goode AP, Shi XA, Gracely RH .
Associations between pressure-pain threshold, symptoms, and radiographic knee and hip osteoarthritis.
Arthritis Care Res. 2014 Oct;66(10):1513-9. doi: 10.1002/acr.22321.
Keywords: Arthritis, Pain, Comparative Effectiveness
Mannion ML, Xie F, Curtis JR
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
The researchers investigated temporal trends in medication use among children diagnosed with juvenile idiopathic arthritis (JIA). They found that the use of tumor necrosis factor inhibitors (TNFi) in the treatment of JIA increased 2- to 3-fold from 2005 to 2012. New TNFi use was associated with decreased NSAID and oral glucocorticoids use. TNFi may be replacing, rather than complementing, methotrexate in the treatment of many patients.
AHRQ-funded; HS018517.
Citation: Mannion ML, Xie F, Curtis JR .
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
J Rheumatol 2014 Oct;41(10):2078-84. doi: 10.3899/jrheum.140012.
.
.
Keywords: Children/Adolescents, Medication, Patient-Centered Outcomes Research, Practice Patterns, Arthritis
Ayers DC, Franklin PD
Joint replacement registries in the United States: a new paradigm.
This commentary serves as an introduction to an upcoming series of articles about orthopaedic registries, in general, with an emphasis on lessons learned from the evolving U.S. and international total joint replacement registries. Specifically, this paper provides an overview of total joint replacement registries and the current expansion of data collection beyond implant attributes and survival to include postoperative complications and patient-reported outcomes.
AHRQ-funded; HS018910.
Citation: Ayers DC, Franklin PD .
Joint replacement registries in the United States: a new paradigm.
J Bone Joint Surg Am 2014 Sep 17;96(18):1567-9. doi: 10.2106/jbjs.n.00641..
Keywords: Arthritis, Chronic Conditions, Patient-Centered Outcomes Research, Registries, Surgery